Latest Materials News

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.

Activeport Group Ltd reported a significant $15.7 million net loss for FY25, driven by a $10.9 million goodwill impairment, as it pivots towards recurring software revenue. The company plans a $2.5 million rights issue to support this transition amid ongoing financial challenges.

Grange Resources reported a 12% drop in revenue and a 48% plunge in profit for the first half of 2025, driven by weaker sales prices and shipment volumes. Despite the downturn, net tangible asset backing per share edged up slightly.

Kalina Power Limited reported a net loss of AUD 4.67 million for FY25 with no revenue generated, while pursuing strategic asset sales and capital raising amid going concern uncertainties.

Camplify Holdings reported a strategic refocus in FY25, delivering a strong operational turnaround in the second half and positioning itself for profitability in FY26. Despite a decline in gross transaction value, the company improved cost efficiency and expanded its membership and insurance offerings.

Cyprium Metals has secured A$80 million through a placement and entitlement offer to fund the restart of its Nifty Copper Complex and reduce existing debt, backed by strong institutional support.

Rapid Critical Metals has initiated a 2,000m diamond drilling campaign at its Webbs Silver Project in NSW, aiming to upgrade its resource to 2025 JORC standards and explore new high-potential silver targets.

Resimac Group Ltd reported a stable FY25 net profit after tax of $34.6 million and declared a fully franked final dividend of 3.5 cents per share, maintaining its steady financial footing amid modest revenue growth.

Vitasora Health reported a sharp rise in losses and operating cash outflows for FY2025, despite achieving significant cost savings from its Orb Health acquisition. The company faces a material uncertainty over its ability to continue as a going concern.

Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.

Horizon Oil Limited reported a 13% increase in production for FY25, driven by the Mereenie acquisition and infill drilling success, while completing a transformative acquisition of Thailand assets. Despite softer oil prices, the company declared a final unfranked dividend, underscoring robust cash flow and strategic growth.

RAS Technology Holdings Limited reported a robust 31% increase in revenue to A$21.3 million for FY25, alongside its first net profit after tax since listing, driven by strategic acquisitions and global expansion.